Core Viewpoint - The company, 百利天恒 (02615), is set to launch an initial public offering (IPO) from November 7 to November 12, 2025, with a global offering of 8.6343 million shares priced between HKD 347.5 and HKD 389 per share, aiming to raise approximately HKD 3.018 billion in net proceeds [1][4]. Group 1: Business Overview - The company operates as a comprehensive medical enterprise with capabilities in early research, clinical development, production, and commercialization, focusing on two main business segments: innovative biopharmaceuticals and generic medicines, including traditional Chinese medicine [1]. - The company has developed a strong expertise in the fields of generic and traditional Chinese medicines since 1996, with a product portfolio covering anesthesia, parenteral nutrition, anti-infection, and pediatrics [3]. Group 2: Research and Development Achievements - Over the past decade, the company has established a research and development platform for innovative antibody-drug conjugates (ADCs), successfully developing 10 ADC candidates that have entered clinical stages, including the globally unique izabren (BL-B01D1) [2]. - The company has also developed a multi-specific T-cell engager platform, resulting in four GNC innovative multi-specific antibody drug candidates that have entered clinical stages, along with an innovative ARC drug development platform [2]. Group 3: Financial and Investment Details - The company has secured cornerstone investment agreements with several investors, including BMS and others, agreeing to subscribe for shares totaling approximately USD 32 million or about HKD 249 million, subject to certain conditions [3]. - The estimated net proceeds from the global offering, based on a median indicative offer price of HKD 368.25 per share, will be allocated as follows: approximately 60% for R&D of biopharmaceutical candidates outside mainland China, 30% for establishing a global supply chain, and 10% for operational funds and general corporate purposes [4].